

U.S. Army Public Health Center

Army Influenza Activity Report


Week ending 31 December 2022 (Week 52)

SUMMARY

Four hundred and thirty-one positive influenza A and 16 influenza B specimens were reported during surveillance Week 52. Additionally, 11 influenza-associated hospitalizations were reported in Week 52; the season total thus far is 136 compared to an average of 43 influenza-associated hospitalizations during the same time period during 2017–2020. Nationwide, influenza activity remains high but continues to decline in most areas, with 15% of specimens tested by clinical laboratories being positive for influenza A or B, according to the Centers for Disease Control and Prevention (CDC). A balanced diet can boost your immune system and help prevent illnesses. Eating five to nine servings of vegetables and fruits daily can provide immune-boosting vitamins, minerals, and antioxidants.

DEMOGRAPHICS

Positive Respiratory Specimen Results from Army MTFs by Age Group and Beneficiary Status, Week 52




AD: One hundred and twenty positive respiratory specimens were collected from AD Service members (SMs) during Week 52; 45% (n=54) of the positive specimens were collected from SMs 18 – 29 years of age.

Non-AD: Four hundred and sixty-seven positive respiratory specimens were collected from non-AD individuals during Week 52; 53.7% (n=251) of the positive specimens were collected from individuals under 18 years of age.

The age and beneficiary status of some cases were not available. Therefore, all calculations involving these variables were conducted using only available data. Differences in total results, and age- and beneficiary status-specific results may be noted throughout the report.

INFLUENZA-ASSOCIATED HOSPITALIZATIONS

Army Influenza-Associated Hospitalizations Reported in DRSi by Onset Week



Eleven influenza-associated hospitalizations among one AD service member and ten non-AD individuals with an onset date in Week 52 were reported to the Disease Reporting System internet (DRSi). The season total thus far is 136 hospitalizations. The Week 52 average during the 2017–2020 seasons was eight hospitalizations (with an average of 34 hospitalizations reported from the start of the season through Week 52).


The DRSi does not capture cases older than 65 years old for influenza-associated hospitalizations.

Data are preliminary and subject to change.


Disclaimer: The mention of any non-federal entity and/or its products is for informational purposes only, and not to be construed or interpreted, in any manner, as federal endorsement of that non-federal entity or its products.

Questions?
[Email APHC DEP](mailto:APHC@armypubmed.mil)

INFLUENZA A ACTIVITY - ARMY



RSV ACTIVITY - ARMY



Of the 3,948 specimens tested for influenza A during Week 52, 10.9% (n=431) were positive. This is a decrease of approximately eight percentage points from Week 51 (18.8%).

Of the 2,084 specimens tested for RSV during Week 52, 3.9% (n=82) were positive. This is a decrease of almost one percentage point from Week 51 (4.4%).



Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.

		Week 49	Week 50	Week 51	Week 52	Season Total
Army MTF Laboratory Results, 2022-23	Adenovirus	30	29	15	15	230
	Enterovirus	29	37	21	23	292
	Influenza A	1,444	1,162	785	431	12,445
	Influenza B	100	59	16	16	429
	Parainfluenza	28	22	11	21	378
	RSV	234	195	92	82	3,538
	Negative	5,618	5,407	3,284	3,420	54,763
	Total	7,483	6,911	4,224	4,008	72,075

Of the 4,008 specimens tested during Week 52, 22.6% (n=588) were positive for any type of respiratory illness. Influenza A accounted for 73.3% (n=431), RSV accounted for 13.9% (n=82), enterovirus accounted for 3.9% (n=23), parainfluenza accounted for 3.6% (n=21), influenza B accounted for 2.7% (n=16), and adenovirus accounted for 2.6% (n=15). Additionally, the reported number of specimens tested decreased by 5.1% from Week 51 to Week 52.

Significantly more tests for influenza have been conducted this season compared to past seasons; 71,333 specimens have been tested for influenza A so far this season compared to the average of 15,670 specimens during the same time period in 2017-2020.

INFLUENZA-LIKE ILLNESS (ILI) ACTIVITY - UNITED STATES




Nationwide in Week 52, incident ILI activity was 5.4%; this is above the national baseline of 2.5%. Additionally, a total of 93,589 specimens were tested for influenza by select clinical laboratories and submitted to the CDC; 14,027 (15.0%) were positive. Influenza A accounted for 99.1% (n=13,905) of the total positive specimens.

Locations providing Week 52 laboratory data as of 5 January 2023: Korea, Carlisle Barracks, Ft. Belvoir, Ft. Benning, Ft. Bliss, Ft. Bragg, Ft. Campbell, Camp Zama, Ft. Carson, Ft. Drum, Ft. Gordon, Ft. Hood, Ft. Huachuca, Ft. Jackson, Ft. Knox, Ft. Leavenworth, Ft. Lee, Ft. Lewis, Ft. Meade, Ft. Riley, Ft. Rucker, Ft. Sam Houston, Ft. Sill, Ft. Stewart, Ft. Wainwright, Landstuhl Regional Medical Center, Redstone Arsenal, Tripler Army Medical Center, and the U.S. Military Academy.


Proportion of Influenza A Positive Specimens by Week and Region, Army Medical Laboratories, 2022–2023 as Compared to 2017–2020*

Regional Health Command - Atlantic (RHC-A)




Week 52			
Age Group	AD	Non-AD	Season Total
< 18	0	26	2,813
18–29	10	10	1,158
30–39	9	6	690
40–49	9	4	332
50–59	2	9	203
60+	0	10	229
Total	30	65	5,425

Regional Health Command - Central (RHC-C)




Week 52			
Age Group	AD	Non-AD	Season Total
< 18	0	66	2,615
18–29	21	22	1,058
30–39	14	17	620
40–49	3	15	308
50–59	1	8	182
60+	0	37	311
Total	39	165	5,094

Regional Health Command - Europe (RHC-E)



Week 52			
Age Group	AD	Non-AD	Season Total
< 18	0	21	533
18–29	7	2	174
30–39	8	8	129
40–49	1	4	60
50–59	2	1	17
60+	0	3	20
Total	18	39	933

Regional Health Command - Pacific (RHC-P)



Week 52			
Age Group	AD	Non-AD	Season Total
< 18	0	27	402
18–29	11	10	228
30–39	6	6	155
40–49	2	4	63
50–59	0	3	33
60+	0	6	81
Total	19	56	962

*2017–2018 influenza season - 2019–2020 influenza season. Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.


Number of Positive Influenza A Specimens by Region and Duty Status

Region	Week 49		Week 50		Week 51		Week 52	
	AD	Non-AD	AD	Non-AD	AD	Non-AD	AD	Non-AD
RHC-A	132	311	82	217	33	101	30	65
RHC-C	144	563	129	481	70	338	39	165
RHC-E	27	83	36	99	37	90	18	39
RHC-P	41	121	44	74	36	80	19	56


U.S. Army Public Health Center
**Army Influenza
Activity Report**

Week ending 31 December 2022 (Week 52)

Positive Respiratory Specimen Results from Army MTFs by Age Group and Beneficiary Status, Week 52



Army Influenza-Associated Hospitalizations Reported in DRSi by Onset Week




U.S. Army Public Health Center

Army Influenza Activity Report

Week ending 31 December 2022 (Week 52)

Proportion of Positive Influenza A Specimens for U.S. Army, 2022-2023




*2017–2018 influenza season - 2019–2020 influenza season. Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.

U.S. Army Public Health Center

Army Influenza Activity Report

Week ending 31 December 2022 (Week 52)

Proportion of Positive Respiratory Syncytial Virus Specimens for U.S. Army, 2022-2023




*2017–2018 influenza season - 2019–2020 influenza season. Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.

U.S. Army Public Health Center

Army Influenza Activity Report

Week ending 31 December 2022 (Week 52)

Percentage of Outpatient Visits for Respiratory Illness Reported By The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2022-2023* and Selected Previous Seasons



Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 2, 2022 – December 17, 2022

